Trial Profile
A trial to study the effects of atomoxetine and osmotic release oral system-methylphenidate on executive functions in patients with combined type attention-deficit/hyperactivity disorder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jun 2016
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary) ; Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- 03 Jun 2016 New trial record